Evan A. Thackaberry
Corporate Officer/Principal en VIGIL NEUROSCIENCE, INC. .
Fortuna: 3 870 $ al 30/04/2024
Perfil
Evan A.
Thackaberry is currently the Senior Vice President & Head-Early Development at Vigil Neuroscience, Inc. Prior to this, he worked as the Vice President-Non Clinical Development at Ra Pharmaceuticals, Inc. from 2017 to 2020.
Thackaberry holds a doctorate degree from the University of Wisconsin.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0.00% | 01/03/2023 | 1 500 ( 0.00% ) | 3 870 $ | 30/04/2024 |
Cargos activos de Evan A. Thackaberry
| Empresas | Cargo | Inicio |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Corporate Officer/Principal | 01/09/2020 |
Antiguos cargos conocidos de Evan A. Thackaberry.
| Empresas | Cargo | Fin |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2020 |
Formación de Evan A. Thackaberry.
| University of Wisconsin | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Evan A. Thackaberry
